Advertisement

Tumor Biology

, Volume 36, Issue 1, pp 95–109 | Cite as

Serum autoantibodies in the early detection of esophageal cancer: a systematic review

  • Hongfei Zhang
  • Junfen Xia
  • Kaijuan Wang
  • Jianying Zhang
Review

Abstract

Antibodies against tumor-associated antigens (TAAs) have been found in serum of patients with various types of cancers and may serve as biomarkers for early detection of esophageal cancer as well. This systematic review aims to give an overview about known autoantibodies and their diagnostic value in esophageal cancer. We conducted a systematic literature search in two databases to identify studies which performed serological testing for autoantibodies in esophageal cancer patients and controls. Data on study characteristics and results were extracted independently by two reviewers. Overall, 45 articles reporting the detection of 35 different autoantibodies met the inclusion criteria of this review. The most common antibody detection method was enzyme-linked immunosorbent assay (ELISA), and the most frequently assessed autoantibody was anti-p53, which was tested in 17 studies and for 15 studies of which a meta-analysis was conducted to comprehensively evaluate the diagnostic value. Most antibodies were assessed in only one study, and only few authors have evaluated the diagnostic value of combinations of multiple autoantibodies. For single autoantibodies, specificity was generally very high (median 98.3 %), but sensitivity was mostly rather low (median 26.7 %). For some autoantibody combinations, substantially higher sensitivity at reasonably high levels of specificity could be achieved. Development of extended and optimized multimarker panels of autoantibodies might be a promising approach for esophageal cancer early detection.

Keywords

Autoantibodies Biomarkers Esophageal cancer Early detection Systematic review 

Notes

Acknowledgement

This study was supported by grants from the Open Science and Technology Cooperation Projects in Henan province (NO.122106000041) and the General Program of National Natural Science Foundation of China (No.81172086 and No.81372371).

Conflicts of interest

None

References

  1. 1.
    Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–907.CrossRefPubMedGoogle Scholar
  2. 2.
    Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, et al. Esophageal cancer–the 5 year survivors. J Surg Oncol. 2011;103:179–83.CrossRefPubMedGoogle Scholar
  5. 5.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  6. 6.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Law S, Wong J. The current management of esophageal cancer. Adv Surg. 2007;41:93–119.CrossRefPubMedGoogle Scholar
  8. 8.
    Headrick JR, Nichols 3rd FC, Miller DL, Allen MS, Trastek VF, Deschamps C, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg. 2002;73:1697–702. discussion 1702–1693.CrossRefPubMedGoogle Scholar
  9. 9.
    Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4:1123–33.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tan HT, Low J, Lim SG, Chung M. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880–904.CrossRefPubMedGoogle Scholar
  11. 11.
    Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Investig. 2001;108:1411–5.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Xu YW, Peng YH, Chen B, Wu ZY, Wu JY, Shen JH, et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 2014;109:36–45.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhou SL, Yue WB, Fan ZM, Du F, Liu BC, Li B, Han XN, Ku JW, Zhao XK, Zhang P, Cui J, Zhou FY, Zhang LQ, Fan XP, Zhou YF, Zhu LL, Liu HY, Wang LD. Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma. Dis Esophagus. 2013;27:790–797. doi: 10.1111/dote.12145.
  15. 15.
    Ye L, Guan S, Zhang C, Lee K-H, Sun S, Wei J, et al. Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumor Biol. 2013;34:1873–7.CrossRefGoogle Scholar
  16. 16.
    Ren P, Ye H, Dai L, Liu M, Liu X, Chai Y, et al. Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma. Oncol Rep. 2013;30:2297–303.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Guan S, Liu B, Zhang C, Lee KH, Sun S, Wei J. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. Clin Transl Oncol. 2013;15:825–9.CrossRefPubMedGoogle Scholar
  18. 18.
    18 Gao H, Zheng Z, Mao Y, Wang W, Qiao Y, Zhou L, Liu F, He H, Zhao X. Identification of tumor antigens that elicit a humoral immune response in the sera of Chinese esophageal squamous cell carcinoma patients by modified serological proteome analysis. Cancer Lett. 2013;344:54–61. doi: 10.1016/j.canlet.2013.
  19. 19.
    Cheng Y, Xu J, Guo J, Jin Y, Wang X, Zhang Q, et al. Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma. Clin Transl Oncol. 2013;15:398–402.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang B, Zhang Z, Zhang X, Gao X, Kernstine KH, Zhong L. Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma. Biomarkers. 2012;17:372–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhou J-H, Zhang B, Kernstine KH, Zhong L. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:1373–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zhang J, Wang K, Zhang J, Liu SS, Dai L, Zhang J-Y. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res. 2011;10:2863–72.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kagaya A, Shimada H, Shiratori T, Kuboshima M, Nakashima-Fujita K, Yasuraoka M, et al. Identification of a novel SEREX antigen family, ECSA, in esophageal squamous cell carcinoma. Proteome Sci. 2011;9:31.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wu M, Mao C, Chen Q, Cu XW, Zhang WS. Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case–control study of 569 patients and 879 healthy controls. Mol Biol Rep. 2010;37:339–43.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu W-L, Guo X-Z, Zhang L-J, Wang J-Y, Zhang G, Guan S, Chen Y-M, Kong Q-L, Xu L-H, Li M-Z, Song L-B, Zeng M-S. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer. 2010;10:467. doi: 10.1186/1471-2407-10-467.
  26. 26.
    Dong J, Zeng B-H, Xu L-H, Wang J-Y, Li M-Z, Zeng M-S, Liu W-L. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med. 2010;8:81. doi: 10.1186/1479-5876-8-81.
  27. 27.
    Shimada H, Shiratori T, Yasuraoka M, Kagaya A, Kuboshima M, Nomura F, et al. Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma. BMC Cancer. 2009;9:232.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Shimada H, Kagaya A, Shiratori T, Nomura F, Takiguchi M, Matsubara H, et al. Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer. J Gastroenterol. 2009;44:691–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Liu W-L, Zhang G, Wang J-Y, Cao J-Y, Guo X-Z, Xu L-H, et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2008;375:440–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Kilic A, Schuchert MJ, Luketich JD, Landreneau RJ, Lokshin AE, Bigbee WL, et al. Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum. J Thorac Cardiovasc Surg. 2008;136:199–204.CrossRefPubMedGoogle Scholar
  31. 31.
    Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 2008;263:280–90.CrossRefPubMedGoogle Scholar
  32. 32.
    Cai H-Y, Wang X-H, Tian Y, Gao L-Y, Zhang L-J, Zhang Z-Y. Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma. World J Gastroenterol. 2008;14:4082–6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, et al. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol. 2007;30:97–103.PubMedGoogle Scholar
  34. 34.
    Gupta G, Sharma R, Chattopadhyay TK, Gupta SD, Ralhan R. Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer. Int J Cancer. 2007;120:1739–47.CrossRefPubMedGoogle Scholar
  35. 35.
    Muller M, Meyer M, Schilling T, Ulsperger E, Lehnert T, Zentgraf H, et al. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol. 2006;29:973–80.PubMedGoogle Scholar
  36. 36.
    Looi K, Megliorino R, Shi F-D, Peng X-X, Chen Y, Zhang J-Y. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 2006;16:1105–10.PubMedGoogle Scholar
  37. 37.
    Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, et al. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 2006;97:380–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, et al. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 2006;28:463–8.PubMedGoogle Scholar
  39. 39.
    Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12:6415–20.CrossRefPubMedGoogle Scholar
  40. 40.
    Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, et al. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer. 2005;114:268–73.CrossRefPubMedGoogle Scholar
  41. 41.
    Su YX, Qian HL, Zhang HY, Wang SY, Shi P, Peng XX. The diversity expression of p62 in digestive system cancers. Clin Immunol. 2005;116:118–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F, et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol. 2005;26:77–86.PubMedGoogle Scholar
  43. 43.
    Megliorino R, Shi FD, Peng XX, Wang X, Chan EK, Tan EM, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev. 2005;29:241–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Kato H, Nakajima M, Fukuchi M, Miyazaki T, Manda R, Kimura H, et al. Serum p53 antibodies in drainage blood from the azygos vein in patients with esophageal carcinoma. Anticancer Res. 2005;25:3231–5.PubMedGoogle Scholar
  45. 45.
    Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029–35.CrossRefPubMedGoogle Scholar
  46. 46.
    Fujita S, Wada H, Jungbluth AA, Sato S, Nakata T, Noguchi Y, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res. 2004;10:6551–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors—a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Kozlowski M, Kovalchuk O, Niklinski J, Chyczewski L, Staroslawska E, Ciechanski A, et al. Circulating anti-p53 antibodies in esophageal cancer patients. Folia Histochem Cytobiol / Pol Acad Sci, Pol Histochem Cytochemical Soc. 2001;39 Suppl 2:173–4.Google Scholar
  50. 50.
    Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.CrossRefPubMedGoogle Scholar
  51. 51.
    Ralhan R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer. 2000;85:791–5.CrossRefPubMedGoogle Scholar
  52. 52.
    Hagiwara N, Onda M, Miyashita M, Sasajima K. Detection of circulating anti-p53 antibodies in esophageal cancer patients. J Nippon Med Sch. 2000;67:110–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Sobti RC, Parashar K. A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutat Res. 1998;422:271–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Shimada H, Nakajima K, Ochiai T, Koide Y, Okazumi SI, Matsubara H, et al. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: Correlation with clinicopathologic features and tumor markers. Oncol Rep. 1998;5:871–4.PubMedGoogle Scholar
  55. 55.
    Cawley HM, Meltzer SJ, De Benedetti VM, Hollstein MC, Muehlbauer KR, Liang L, et al. Anti-p53 antibodies in patients with Barrett’s esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology. 1998;115:19–27.CrossRefPubMedGoogle Scholar
  56. 56.
    Kamei M, Kato M, Mochizuki K, Kuroda K, Sato S, Hashizume S, Yasumoto K, Murakami H, Nomoto K. Serodiagnosis of cancers by ELISA of anti-histone H2B antibody. Biotherapy. 1992;4:17–22.Google Scholar
  57. 57.
    Veale RB, Thornley AL, Scott E, Antoni A, Segal I. Quantitation of autoantibodies to cytokeratins in sera from patients with squamous cell carcinoma of the oesophagus. Br J Cancer. 1988;58:767–72.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Zaenker P, Ziman MR. Serologic autoantibodies as diagnostic cancer biomarkers—a review. Cancer Epidemiol Biomarkers Prev. 2013;22:2161–81.CrossRefPubMedGoogle Scholar
  59. 59.
    Finn OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med. 2005;353:1288–90.CrossRefPubMedGoogle Scholar
  60. 60.
    Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008;222:328–40.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 2008;7:1388–94.CrossRefPubMedGoogle Scholar
  62. 62.
    Levenson VV. Biomarkers for early detection of breast cancer: what, when, and where? Biochim Biophys Acta. 2007;1770:847–56.CrossRefPubMedGoogle Scholar
  63. 63.
    Graham JB, Graham RM. Antibodies elicited by cancer in patients. Cancer. 1955;8:409–16.CrossRefPubMedGoogle Scholar
  64. 64.
    GOLD P. Circulating antibodies against carcinoembryonic antigens of the human digestive system. Cancer. 1967;20:1663–7.CrossRefGoogle Scholar
  65. 65.
    Werner S, Chen H, Tao S, Brenner H. systematic review: Serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2014. doi: 10.1002/ijc.28807
  66. 66.
    Ziegler A, Konig IR, Schulz-Knappe P. Challenges in planning and conducting diagnostic studies with molecular biomarkers. Dtsch Med Wochenschr. 2013;138:e2–24.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hongfei Zhang
    • 1
    • 2
  • Junfen Xia
    • 1
    • 2
  • Kaijuan Wang
    • 1
    • 2
  • Jianying Zhang
    • 1
    • 2
  1. 1.College of Public HealthZhengzhou UniversityZhengzhouChina
  2. 2.Henan Key Laboratory of Tumor EpidemiologyZhengzhou UniversityZhengzhouChina

Personalised recommendations